Recent LPCN News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 01:00:30 PM
- Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024 • PR Newswire (US) • 06/10/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:48:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:45:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:43:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:41:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:39:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 08:32:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 09:15:12 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/03/2024 09:09:23 PM
- Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024 • PR Newswire (US) • 05/09/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 10:06:19 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 10:03:08 AM
- Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024 • PR Newswire (US) • 05/08/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 10:15:30 AM
- Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154 • PR Newswire (US) • 05/01/2024 12:00:00 PM
- Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity • PR Newswire (US) • 04/11/2024 11:00:00 AM
- Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis • PR Newswire (US) • 03/28/2024 12:00:00 PM
- Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154 • PR Newswire (US) • 03/25/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 10:31:06 PM
- Lipocine Announces Financial Results for the Full Year Ended December 31, 2023 • PR Newswire (US) • 03/07/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:08:06 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/07/2024 11:07:26 AM
- Lipocine to Present at 36th Annual Roth Conference • PR Newswire (US) • 03/06/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 11:01:31 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM